Who are Exdensur's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Wakix, Lastacaft, Xyzal, Elestat, Clarinex, Rupax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/depemokimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Exdensur — Competitive Intelligence Brief

Exdensur (DEPEMOKIMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Respiratory.

marketed Histamine Respiratory Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Exdensur (DEPEMOKIMAB) — Glaxosmithkline Llc. Exdensur works by binding to histamine, preventing it from interacting with its receptors and reducing inflammation and airway constriction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Exdensur TARGET	DEPEMOKIMAB	Glaxosmithkline Llc	marketed		Histamine	2025-01-01
Wakix	PITOLISANT	Harmony	marketed		Histamine H3 receptor	2019-01-01
Lastacaft	ALCAFTADINE	AbbVie	marketed	Histamine-1 Receptor Antagonist [EPC]	Histamine H1 receptor	2010-01-01
Xyzal	LEVOCETIRIZINE	Sanofi	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Elestat	EPINASTINE	AbbVie	marketed	Adrenergic Receptor Agonist	Histamine H1 receptor	2003-01-01
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	marketed	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Rupax	RUPATADINE	Teikoku Seiyaku	marketed	rupatadine	Histamine H1 receptor	2001-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exdensur — Competitive Intelligence Brief. https://druglandscape.com/ci/depemokimab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab